Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00719914
Other study ID # T101
Secondary ID
Status Terminated
Phase Phase 2
First received January 7, 2008
Last updated July 24, 2012
Start date November 2007
Est. completion date January 2009

Study information

Verified date July 2012
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly after arriving. This drug is usually given through a vein in the arm. However, eptifibatide can also be injected directly into the heart's blood supply just before angioplasty, a common procedure to unblock a blood vessel in the heart. This new way of giving the drug is being studying.


Description:

The primary objective of the IC-TITAN study is to demonstrate that an IC bolus of eptifibatide added to an upstream double-bolus and infusion regimen of eptifibatide administered intravenously and initiated early in the ER will result in significant additional clot resolution in vivo when compared with an IC injection of placebo (saline). The primary endpoint chosen to evaluate this hypothesis is the improvement in percent diameter stenosis of the culprit artery following the IC bolus administration of eptifibatide vs. IC placebo (saline) as assessed with quantitative coronary angiography (QCA).


Recruitment information / eligibility

Status Terminated
Enrollment 31
Est. completion date January 2009
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Clinical

- Patients (men or women) at least 18 years of age and

- Presenting with ischemic chest discomfort >20 minutes and <6 hours of duration suggestive of acute myocardial infarction

AND:

ECG

- ST elevation >1mm (>0.1mV) in two contiguous limb leads OR >2mm (>0.2mV) in two contiguous precordial leads

Exclusion Criteria:

CLINICAL

- Maximal systolic blood pressure <80 mmHg AFTER initial fluid and/or pressor resuscitation

- Uncontrolled hypertension (SBP>180 OR DBP >110) at time of enrollment

- Ventricular fibrillation or ventricular tachycardia requiring DC cardioversion

- Sinus bradycardia (HR <50/min), third degree or advanced second degree heart block.

- Known pregnancy

- New or suspected new left bundle branch block

BIOCHEMICAL

- Known thrombocytopenia (platelet count <100,000)

- Known severe renal insufficiency (creatinine >4.0 mg/dL)

INCREASED BLEEDING RISK

- Active or recent (<1 year) bleeding or gastrointestinal hemorrhage

- Major surgery <1 month

- Known coagulopathy, platelet disorder or history of thrombocytopenia: If a patient is known to be on chronic warfarin therapy, the International Normalized Ratio (INR) must be known to be <1.6 in order for the patient to be included

- Known neoplasm

- Any history of hemorrhagic cerebrovascular disorder or active intracranial pathology

MEDICATIONS

- Administration of a fibrinolytic agent within 7 days

- Known allergy or contraindication to eptifibatide OR aspirin OR heparin

- Treatment with another GP IIb/IIIa inhibitor within 7 days

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
eptifibatide
Intra-coronary injection, weight based, of eptifibatide.
eptifibatide
Intra-coronary injection, based on weight, of eptifibatide
normal saline
Intra-coronary injection, weight based, of normal saline.

Locations

Country Name City State
United States Mid Ohio Heart Clinic Mansfield Ohio
United States Cardiology Research Associates Ormond Beach Florida
United States Crittenton Hospital Medical Center Rochester Michigan

Sponsors (2)

Lead Sponsor Collaborator
Brigham and Women's Hospital Schering-Plough

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in Percent Diameter Stenosis of the Culprit Artery Following the IC Bolus Administration of Eptifibatide vs. IC Placebo (Saline) as Assessed With Quantitative Coronary Angiography (QCA) 30 days No
See also
  Status Clinical Trial Phase
Completed NCT01864343 - Target Temperature Management In Myocardial Infarction - A Pilot Study N/A
Completed NCT00962416 - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI) Phase 4
Active, not recruiting NCT00927615 - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) N/A
Completed NCT03135275 - MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial N/A
Recruiting NCT02592694 - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty Phase 4
Withdrawn NCT01991366 - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed NCT02158468 - Effect of Conditioning on Myocardial Damage in STEMI N/A
Completed NCT01197729 - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry N/A
Completed NCT06426537 - Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches Early Phase 1
Completed NCT01882179 - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size Phase 3
Completed NCT00952224 - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome N/A
Completed NCT00378391 - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry N/A
Withdrawn NCT04303377 - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction Phase 2
Completed NCT03523624 - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed NCT01531114 - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus Phase 3
Active, not recruiting NCT01960933 - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization N/A
Completed NCT00502528 - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction Phase 2
Recruiting NCT02062554 - Brasilia Heart Study
Recruiting NCT04150016 - In-stent Repair and Vessel Reaction of STEMI Patients With OCT N/A
Recruiting NCT03074214 - Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction N/A